Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Nuclear Medicine and Cancer Theragnostics

Vasiliki Zoi
,
Maria Giannakopoulou
,
George A Alexiou
,
Pinelopi Bouziotis
ORCID logo ,
Savvas Thalasselis
ORCID logo ,
Andreas G Tzakos
ORCID logo ,
Andreas Fotopoulos
,
Athanassios P Kyritsis
* ORCID logo ,
Chrissa Sioka
Version 1 : Received: 11 September 2023 / Approved: 12 September 2023 / Online: 12 September 2023 (08:51:02 CEST)

A peer-reviewed article of this Preprint also exists.

Zoi, V.; Giannakopoulou, M.; Alexiou, G.A.; Bouziotis, P.; Thalasselis, S.; Tzakos, A.G.; Fotopoulos, A.; Papadopoulos, A.N.; Kyritsis, A.P.; Sioka, C. Nuclear Medicine and Cancer Theragnostics: Basic Concepts. Diagnostics 2023, 13, 3064. Zoi, V.; Giannakopoulou, M.; Alexiou, G.A.; Bouziotis, P.; Thalasselis, S.; Tzakos, A.G.; Fotopoulos, A.; Papadopoulos, A.N.; Kyritsis, A.P.; Sioka, C. Nuclear Medicine and Cancer Theragnostics: Basic Concepts. Diagnostics 2023, 13, 3064.

Abstract

Cancer theragnostics is a novel approach that combines diagnostic imaging and radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized for positron emission tomography imaging, through linkage to a proper radionuclide, and the other bearing a beta-emitter isotope that can induce significant damage to cancer cells. In recent years, the use of theragnostics in nuclear medicine clinical practice has increased considerably, and thus investigation has focused on the identification of novel radionuclides that can bind to molecular targets which are typically dysregulated in different cancers. The major advantages of the theragnostic approach include elimination of multi-step procedures, reduced adverse effects to normal tissues, early diagnosis, better predicting responses and personalized patient care. This review aims to discuss emerging theragnostic molecules that have been investigated in a series of human malignancies, including gliomas, thyroid cancer, neuroendocrine tumors, cholangiocarcinoma and prostate cancer, as well as potent and recently introduced molecular targets, like cell-surface receptors, kinases, and cell adhesion proteins. Furthermore, special reference has been made to copper radionuclides as theragnostic agents, and their radiopharmaceutical applications since they present promising alternatives to the well-studied gallium-68 and lutetium-177.

Keywords

Theragnostics; nuclear medicine; thyroid cancer; neuroendocrine tumors; prostate cancer; colorectal cancer; cholangiocarcinoma; glioma

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.